Company intelligence / Profile preview

Thomas J. Shaw

Little Elm, Texas, United States

Ownership: Public · RVP
Development stage: Other

Overview

Retractable Technologies has commercialized the VanishPoint safety syringe product line, FDA approved for multiple syringe formats and blood collection devices. Clinical studies and legislative recognition contributed to regulatory adoption focused on needlestick injury prevention.

Therapeutic areas: HematologyInfectious DiseasesOther
Modalities: Device
Industry: Consumable Medical Devices

Partnerships

Kaiser PermanenteService Employees International Union

Beyond the preview

Go deeper on Thomas J. Shaw.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thomas J. Shaw.

Explore the full profile